Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-01-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2019.1597644 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850265960137621504 |
|---|---|
| author | Ivy Widjaja Chunyan Wang Rien van Haperen Javier Gutiérrez-Álvarez Brenda van Dieren Nisreen M.A. Okba V. Stalin Raj Wentao Li Raul Fernandez-Delgado Frank Grosveld Frank J. M. van Kuppeveld Bart L. Haagmans Luis Enjuanes Dubravka Drabek Berend-Jan Bosch |
| author_facet | Ivy Widjaja Chunyan Wang Rien van Haperen Javier Gutiérrez-Álvarez Brenda van Dieren Nisreen M.A. Okba V. Stalin Raj Wentao Li Raul Fernandez-Delgado Frank Grosveld Frank J. M. van Kuppeveld Bart L. Haagmans Luis Enjuanes Dubravka Drabek Berend-Jan Bosch |
| author_sort | Ivy Widjaja |
| collection | DOAJ |
| description | The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively, these antibodies offer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting different spike protein epitopes and functions. |
| format | Article |
| id | doaj-art-c5a58e9203e14de48fe994d1b6032c31 |
| institution | OA Journals |
| issn | 2222-1751 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Emerging Microbes and Infections |
| spelling | doaj-art-c5a58e9203e14de48fe994d1b6032c312025-08-20T01:54:16ZengTaylor & Francis GroupEmerging Microbes and Infections2222-17512019-01-018151653010.1080/22221751.2019.1597644Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoproteinIvy Widjaja0Chunyan Wang1Rien van Haperen2Javier Gutiérrez-Álvarez3Brenda van Dieren4Nisreen M.A. Okba5V. Stalin Raj6Wentao Li7Raul Fernandez-Delgado8Frank Grosveld9Frank J. M. van Kuppeveld10Bart L. Haagmans11Luis Enjuanes12Dubravka Drabek13Berend-Jan Bosch14Virology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, NetherlandsVirology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, NetherlandsDepartment of Cell Biology, Erasmus MC, Rotterdam, NetherlandsDepartment of Molecular and Cell Biology, National Center for Biotechnology-Spanish National Research Council (CNB-CSIC), Madrid, SpainVirology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, NetherlandsDepartment of Viroscience, Erasmus Medical Center, Rotterdam, NetherlandsDepartment of Viroscience, Erasmus Medical Center, Rotterdam, NetherlandsVirology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, NetherlandsDepartment of Molecular and Cell Biology, National Center for Biotechnology-Spanish National Research Council (CNB-CSIC), Madrid, SpainDepartment of Cell Biology, Erasmus MC, Rotterdam, NetherlandsVirology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, NetherlandsDepartment of Viroscience, Erasmus Medical Center, Rotterdam, NetherlandsDepartment of Molecular and Cell Biology, National Center for Biotechnology-Spanish National Research Council (CNB-CSIC), Madrid, SpainDepartment of Cell Biology, Erasmus MC, Rotterdam, NetherlandsVirology Division, Department of Infectious Diseases & Immunology, Faculty of Veterinary Medicine, Utrecht University, Utrecht, NetherlandsThe Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively, these antibodies offer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting different spike protein epitopes and functions.https://www.tandfonline.com/doi/10.1080/22221751.2019.1597644CoronavirusMERSantibodiesspike protein |
| spellingShingle | Ivy Widjaja Chunyan Wang Rien van Haperen Javier Gutiérrez-Álvarez Brenda van Dieren Nisreen M.A. Okba V. Stalin Raj Wentao Li Raul Fernandez-Delgado Frank Grosveld Frank J. M. van Kuppeveld Bart L. Haagmans Luis Enjuanes Dubravka Drabek Berend-Jan Bosch Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein Emerging Microbes and Infections Coronavirus MERS antibodies spike protein |
| title | Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein |
| title_full | Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein |
| title_fullStr | Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein |
| title_full_unstemmed | Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein |
| title_short | Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein |
| title_sort | towards a solution to mers protective human monoclonal antibodies targeting different domains and functions of the mers coronavirus spike glycoprotein |
| topic | Coronavirus MERS antibodies spike protein |
| url | https://www.tandfonline.com/doi/10.1080/22221751.2019.1597644 |
| work_keys_str_mv | AT ivywidjaja towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT chunyanwang towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT rienvanhaperen towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT javiergutierrezalvarez towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT brendavandieren towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT nisreenmaokba towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT vstalinraj towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT wentaoli towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT raulfernandezdelgado towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT frankgrosveld towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT frankjmvankuppeveld towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT bartlhaagmans towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT luisenjuanes towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT dubravkadrabek towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein AT berendjanbosch towardsasolutiontomersprotectivehumanmonoclonalantibodiestargetingdifferentdomainsandfunctionsofthemerscoronavirusspikeglycoprotein |